Heart failure (HF) is a condition in which the heart does not contract ("pump") or relax
well, leading to insufficient perfusion of vital organs. Ankle swelling, fatigue, and
breathlessness are some of the features of this syndrome. There are different causes for HF
(eg., infarct and hypertension) and two distinct types: HFrEF - HF with reduced ejection
fraction - where the heart does not "pump" properly, and HFpEF - HF with preserved ejection
fraction - the heart "pumps" but does not relax well. Treatment for HFrEF is better
established than for HFpEF. In HFpEF, only mineralocorticoid receptors antagonists (MRAs)
have been shown to reduce hospitalizations, circulating markers of cardiac dysfunction and
fibrosis, and blood pressure. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a
therapeutic class that reduces morbidity and mortality in patients with high cardiovascular
risk and diabetes and in patients with HFrEF with and without diabetes. Trials are underway
to test whether SGLT2i may also be useful for the treatment of HFpEF. This work aims to
compare the effects of MRAs and SGLT2i alone, plus their combination in patients with HFpEF.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Universidade do Porto
Collaborators:
Centro Hospitalar De São João, E.P.E. (CHUSJ) Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.